JESDUVROQ

Peak

daprodustat

NDAORALTABLET
Approved
Feb 2023
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
16

Mechanism of Action

Hypoxia-Inducible Factor Prolyl Hydroxylase Inhibitors

Pharmacologic Class:

Hypoxia-inducible Factor Prolyl Hydroxylase Inhibitor

Clinical Trials (5)

NCT07300111Phase 3Not Yet Recruiting

A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD)

Started Dec 2025
100 enrolled
Anaemia
NCT05682326Phase 3Completed

Anemia Studies in CKD: Erythropoiesis Via a Novel PHI Daprodustat - Pediatric (ASCEND-P)

Started Sep 2023
4 enrolled
Anaemia
NCT05951192Phase 4Completed

A Prospective Interventional Study Assessing the Clinical and Operational Effectiveness of Transitioning From Mircera to Daprodustat for the Treatment of Anemia in End Stage Kidney Disease

Started Jul 2023
161 enrolled
AnemiaRenal Insufficiency, ChronicRenal Anemia
NCT04640311Phase 1Completed

Comparison of Daprodustat Formulations Produced by Two Methods of Manufacture for Bioequivalence and Dissolution in Healthy Participants

Started Dec 2020
259 enrolled
Anaemia
NCT03457701Phase 2Completed

Anemia Studies in CKD: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat- Iron (ASCEND: Fe)

Started Jul 2019
15 enrolled
Anaemia

Loss of Exclusivity

LOE Date
Mar 13, 2038
146 months away
Patent Expiry
Mar 13, 2038
Exclusivity Expiry
Feb 1, 2028

Patent Records (5)

Patent #ExpiryTypeUse Code
11643397
Jun 22, 2027
Substance
U-3535
8557834
Jun 22, 2027
U-1238
8815884
Jun 22, 2027
Product
U-1238
8324208
Dec 11, 2028
SubstanceProduct
11117871
Mar 13, 2038
SubstanceProduct
U-3535